Search tips
Search criteria 


Logo of envhperEnvironmental Health PerspectivesBrowse ArticlesAbout EHPGeneral InformationAuthorsMediaProgramsPartnerships
Environ Health Perspect. 1999 May; 107(5): 359–365.
PMCID: PMC1566417
Research Article

Drinking water arsenic in Utah: A cohort mortality study.


The association of drinking water arsenic and mortality outcome was investigated in a cohort of residents from Millard County, Utah. Median drinking water arsenic concentrations for selected study towns ranged from 14 to 166 ppb and were from public and private samples collected and analyzed under the auspices of the State of Utah Department of Environmental Quality, Division of Drinking Water. Cohort members were assembled using historical documents of the Church of Jesus Christ of Latter-day Saints. Standard mortality ratios (SMRs) were calculated. Using residence history and median drinking water arsenic concentration, a matrix for cumulative arsenic exposure was created. Without regard to specific exposure levels, statistically significant findings include increased mortality from hypertensive heart disease [SMR = 2.20; 95% confidence interval (CI), 1.36-3.36], nephritis and nephrosis (SMR = 1.72; CI, 1.13-2.50), and prostate cancer (SMR = 1.45; CI, 1.07-1. 91) among cohort males. Among cohort females, statistically significant increased mortality was found for hypertensive heart disease (SMR = 1.73; CI, 1.11-2.58) and for the category of all other heart disease, which includes pulmonary heart disease, pericarditis, and other diseases of the pericardium (SMR = 1.43; CI, 1.11-1.80). SMR analysis by low, medium, and high arsenic exposure groups hinted at a dose relationship for prostate cancer. Although the SMRs by exposure category were elevated for hypertensive heart disease for both males and females, the increases were not sequential from low to high groups. Because the relationship between health effects and exposure to drinking water arsenic is not well established in U.S. populations, further evaluation of effects in low-exposure populations is warranted.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (2.2M), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Tseng WP, Chu HM, How SW, Fong JM, Lin CS, Yeh S. Prevalence of skin cancer in an endemic area of chronic arsenicism in Taiwan. J Natl Cancer Inst. 1968 Mar;40(3):453–463. [PubMed]
  • Tseng WP. Effects and dose--response relationships of skin cancer and blackfoot disease with arsenic. Environ Health Perspect. 1977 Aug;19:109–119. [PMC free article] [PubMed]
  • Morton W, Starr G, Pohl D, Stoner J, Wagner S, Weswig D. Skin cancer and water arsenic in Lane County, Oregon. Cancer. 1976 May;37(5):2523–2532. [PubMed]
  • Harrington JM, Middaugh JP, Morse DL, Housworth J. A survey of a population exposed to high concentrations of arsenic in well water in Fairbanks, Alaska. Am J Epidemiol. 1978 Nov;108(5):377–385. [PubMed]
  • Kreiss K, Zack MM, Landrigan PJ, Feldman RG, Niles CA, Chirico-Post J, Sax DS, Boyd MH, Cox DH. Neurologic evaluation of a population exposed to arsenic in Alaskan well water. Arch Environ Health. 1983 Mar-Apr;38(2):116–121. [PubMed]
  • Wong O, Whorton MD, Foliart DE, Lowengart R. An ecologic study of skin cancer and environmental arsenic exposure. Int Arch Occup Environ Health. 1992;64(4):235–241. [PubMed]
  • Bates MN, Smith AH, Cantor KP. Case-control study of bladder cancer and arsenic in drinking water. Am J Epidemiol. 1995 Mar 15;141(6):523–530. [PubMed]
  • Engel RR, Smith AH. Arsenic in drinking water and mortality from vascular disease: an ecologic analysis in 30 counties in the United States. Arch Environ Health. 1994 Sep-Oct;49(5):418–427. [PubMed]
  • Aschengrau A, Zierler S, Cohen A. Quality of community drinking water and the occurrence of spontaneous abortion. Arch Environ Health. 1989 Sep-Oct;44(5):283–290. [PubMed]
  • Zierler S, Theodore M, Cohen A, Rothman KJ. Chemical quality of maternal drinking water and congenital heart disease. Int J Epidemiol. 1988 Sep;17(3):589–594. [PubMed]
  • Feinglass EJ. Arsenic intoxication from well water in the United States. N Engl J Med. 1973 Apr 19;288(16):828–830. [PubMed]
  • Warner ML, Moore LE, Smith MT, Kalman DA, Fanning E, Smith AH. Increased micronuclei in exfoliated bladder cells of individuals who chronically ingest arsenic-contaminated water in Nevada. Cancer Epidemiol Biomarkers Prev. 1994 Oct-Nov;3(7):583–590. [PubMed]
  • Chen CJ, Hsueh YM, Lai MS, Shyu MP, Chen SY, Wu MM, Kuo TL, Tai TY. Increased prevalence of hypertension and long-term arsenic exposure. Hypertension. 1995 Jan;25(1):53–60. [PubMed]
  • Chen CJ, Chiou HY, Chiang MH, Lin LJ, Tai TY. Dose-response relationship between ischemic heart disease mortality and long-term arsenic exposure. Arterioscler Thromb Vasc Biol. 1996 Apr;16(4):504–510. [PubMed]
  • Chen CJ, Chuang YC, Lin TM, Wu HY. Malignant neoplasms among residents of a blackfoot disease-endemic area in Taiwan: high-arsenic artesian well water and cancers. Cancer Res. 1985 Nov;45(11 Pt 2):5895–5899. [PubMed]
  • Hopenhayn-Rich C, Biggs ML, Fuchs A, Bergoglio R, Tello EE, Nicolli H, Smith AH. Bladder cancer mortality associated with arsenic in drinking water in Argentina. Epidemiology. 1996 Mar;7(2):117–124. [PubMed]
  • Chen CJ, Chuang YC, You SL, Lin TM, Wu HY. A retrospective study on malignant neoplasms of bladder, lung and liver in blackfoot disease endemic area in Taiwan. Br J Cancer. 1986 Mar;53(3):399–405. [PubMed]
  • Chen CJ, Wu MM, Lee SS, Wang JD, Cheng SH, Wu HY. Atherogenicity and carcinogenicity of high-arsenic artesian well water. Multiple risk factors and related malignant neoplasms of blackfoot disease. Arteriosclerosis. 1988 Sep-Oct;8(5):452–460. [PubMed]
  • Chen CJ, Wang CJ. Ecological correlation between arsenic level in well water and age-adjusted mortality from malignant neoplasms. Cancer Res. 1990 Sep 1;50(17):5470–5474. [PubMed]
  • Chen CJ, Chen CW, Wu MM, Kuo TL. Cancer potential in liver, lung, bladder and kidney due to ingested inorganic arsenic in drinking water. Br J Cancer. 1992 Nov;66(5):888–892. [PubMed]
  • Chiang HS, Guo HR, Hong CL, Lin SM, Lee EF. The incidence of bladder cancer in the black foot disease endemic area in Taiwan. Br J Urol. 1993 Mar;71(3):274–278. [PubMed]
  • Chiou HY, Hsueh YM, Liaw KF, Horng SF, Chiang MH, Pu YS, Lin JS, Huang CH, Chen CJ. Incidence of internal cancers and ingested inorganic arsenic: a seven-year follow-up study in Taiwan. Cancer Res. 1995 Mar 15;55(6):1296–1300. [PubMed]
  • Smith AH, Goycolea M, Haque R, Biggs ML. Marked increase in bladder and lung cancer mortality in a region of Northern Chile due to arsenic in drinking water. Am J Epidemiol. 1998 Apr 1;147(7):660–669. [PubMed]
  • Wu MM, Kuo TL, Hwang YH, Chen CJ. Dose-response relation between arsenic concentration in well water and mortality from cancers and vascular diseases. Am J Epidemiol. 1989 Dec;130(6):1123–1132. [PubMed]
  • Chiou HY, Huang WI, Su CL, Chang SF, Hsu YH, Chen CJ. Dose-response relationship between prevalence of cerebrovascular disease and ingested inorganic arsenic. Stroke. 1997 Sep;28(9):1717–1723. [PubMed]
  • Lai MS, Hsueh YM, Chen CJ, Shyu MP, Chen SY, Kuo TL, Wu MM, Tai TY. Ingested inorganic arsenic and prevalence of diabetes mellitus. Am J Epidemiol. 1994 Mar 1;139(5):484–492. [PubMed]
  • Rahman M, Tondel M, Ahmad SA, Axelson O. Diabetes mellitus associated with arsenic exposure in Bangladesh. Am J Epidemiol. 1998 Jul 15;148(2):198–203. [PubMed]
  • Valentine JL, He SY, Reisbord LS, Lachenbruch PA. Health response by questionnaire in arsenic-exposed populations. J Clin Epidemiol. 1992 May;45(5):487–494. [PubMed]
  • Borgoño JM, Vicent P, Venturino H, Infante A. Arsenic in the drinking water of the city of Antofagasta: epidemiological and clinical study before and after the installation of a treatment plant. Environ Health Perspect. 1977 Aug;19:103–105. [PMC free article] [PubMed]
  • Ross R. The pathogenesis of atherosclerosis--an update. N Engl J Med. 1986 Feb 20;314(8):488–500. [PubMed]
  • Hansen ES. International Commission for Protection Against Environmental Mutagens and Carcinogens. ICPEMC Working Paper 7/1/2. Shared risk factors for cancer and atherosclerosis--a review of the epidemiological evidence. Mutat Res. 1990 Nov;239(3):163–179. [PubMed]
  • Lyon JL, Gardner K, Gress RE. Cancer incidence among Mormons and non-Mormons in Utah (United States) 1971-85. Cancer Causes Control. 1994 Mar;5(2):149–156. [PubMed]
  • Lyon JL, Klauber MR, Gardner JW, Smart CR. Cancer incidence in Mormons and non-Mormons in Utah, 1966-1970. N Engl J Med. 1976 Jan 15;294(3):129–133. [PubMed]
  • WOOLF CM. An investigation of the familial aspects of carcinoma of the prostate. Cancer. 1960 Jul-Aug;13:739–744. [PubMed]
  • Enterline PE, Henderson VL, Marsh GM. Exposure to arsenic and respiratory cancer. A reanalysis. Am J Epidemiol. 1987 Jun;125(6):929–938. [PubMed]
  • Simonato L, Moulin JJ, Javelaud B, Ferro G, Wild P, Winkelmann R, Saracci R. A retrospective mortality study of workers exposed to arsenic in a gold mine and refinery in France. Am J Ind Med. 1994 May;25(5):625–633. [PubMed]
  • Rothman KJ. No adjustments are needed for multiple comparisons. Epidemiology. 1990 Jan;1(1):43–46. [PubMed]
  • Yamauchi H, Yamamura Y. Concentration and chemical species of arsenic in human tissue. Bull Environ Contam Toxicol. 1983 Sep;31(3):267–270. [PubMed]
  • Gerhardsson L, Dahlgren E, Eriksson A, Lagerkvist BE, Lundström J, Nordberg GF. Fatal arsenic poisoning--a case report. Scand J Work Environ Health. 1988 Apr;14(2):130–133. [PubMed]
  • Lerman S, Clarkson TW. The metabolism of arsenite and arsenate by the rat. Fundam Appl Toxicol. 1983 Jul-Aug;3(4):309–314. [PubMed]

Articles from Environmental Health Perspectives are provided here courtesy of National Institute of Environmental Health Science